Latest news with #Eversense365
Yahoo
21-05-2025
- Business
- Yahoo
Senseonics Holdings, Inc. Announces Closing of Public Offering, Including Exercise in Full of the Underwriters' Option to Purchase Additional Shares, and Closing of Private Placement
Public offering results in gross proceeds of $57.5 million Private placement results in gross proceeds of approximately $20.3 million GERMANTOWN, Md., May 21, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced the closing of its previously announced underwritten public offering of a total of 115,000,000 shares of its common stock, which included the exercise in full by the underwriters of their option to purchase up to an additional 15,000,000 shares of common stock, at a public offering price of $0.50 per share. The aggregate gross proceeds from the public offering, before deducting underwriting discounts and commissions and offering expenses were $57.5 million. All of the shares in the offering were sold by Senseonics. In connection with the public offering, Senseonics entered into a stock purchase agreement with Abbott Laboratories for the issuance of shares of Senseonics' common stock representing 4.99% of Senseonics' outstanding common stock following the closing of both offerings at a price per share equal to the public offering price. In the closing of the private placement, Abbott acquired 40,539,265 shares for an aggregate purchase price of approximately $20.3 million, before offering expenses. Senseonics intends to use the net proceeds from the public offering and private placement to fund the ongoing launch of Eversense 365 and continued development of pipeline products, as well as for working capital and general corporate purposes. TD Cowen and Barclays acted as joint book-running managers and RBC Capital Markets and Lake Street acted as bookrunners for the public offering. The public offering was made pursuant to a 'shelf' registration statement on Form S-3, including a base prospectus (File No. 333-273882) that was originally filed with the Securities and Exchange Commission (the 'SEC') on August 10, 2023 and became effective on September 12, 2023. The offering was made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A final prospectus supplement and accompanying prospectus relating to the offering has been filed with the SEC and is available on the SEC's website at Copies of the final prospectus supplement and the accompanying prospectus may also be obtained by contacting TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, NY 10017, by telephone at (833) 297-2926 or by email at or Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at 1-888-603-5847, or by email at barclaysprospectus@ This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About Senseonics Senseonics Holdings, Inc. ("Senseonics") is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM systems Eversense® 365 and Eversense® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone. Forward-Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including without limitation statements regarding, among other things, Senseonics' expectations about the anticipated use of proceeds from the offerings. The words 'expects,' 'potential,' 'may,' 'will,' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including uncertainties relating to the current economic environment, market and other conditions; and other risks and uncertainties that are described in the Risk Factors section of Senseonics' Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 3, 2025, Senseonics' Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 8, 2025, Senseonics' final prospectus supplement for the public offering dated May 15, 2025, filed with the SEC on May 16, 2025, and other filings Senseonics makes with the SEC from time to time. The events and circumstances discussed in such forward-looking statements may not occur, and Senseonics' actual results could differ materially and adversely from those anticipated or implied thereby. Any forward-looking statements contained in this press release speak only as of the date hereof, and Senseonics expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise. INVESTOR CONTACT:Jeremy FefferLifeSci Advisorsinvestors@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21-05-2025
- Business
- Yahoo
Senseonics Holdings, Inc. Announces Closing of Public Offering, Including Exercise in Full of the Underwriters' Option to Purchase Additional Shares, and Closing of Private Placement
Public offering results in gross proceeds of $57.5 million Private placement results in gross proceeds of approximately $20.3 million GERMANTOWN, Md., May 21, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced the closing of its previously announced underwritten public offering of a total of 115,000,000 shares of its common stock, which included the exercise in full by the underwriters of their option to purchase up to an additional 15,000,000 shares of common stock, at a public offering price of $0.50 per share. The aggregate gross proceeds from the public offering, before deducting underwriting discounts and commissions and offering expenses were $57.5 million. All of the shares in the offering were sold by Senseonics. In connection with the public offering, Senseonics entered into a stock purchase agreement with Abbott Laboratories for the issuance of shares of Senseonics' common stock representing 4.99% of Senseonics' outstanding common stock following the closing of both offerings at a price per share equal to the public offering price. In the closing of the private placement, Abbott acquired 40,539,265 shares for an aggregate purchase price of approximately $20.3 million, before offering expenses. Senseonics intends to use the net proceeds from the public offering and private placement to fund the ongoing launch of Eversense 365 and continued development of pipeline products, as well as for working capital and general corporate purposes. TD Cowen and Barclays acted as joint book-running managers and RBC Capital Markets and Lake Street acted as bookrunners for the public offering. The public offering was made pursuant to a 'shelf' registration statement on Form S-3, including a base prospectus (File No. 333-273882) that was originally filed with the Securities and Exchange Commission (the 'SEC') on August 10, 2023 and became effective on September 12, 2023. The offering was made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A final prospectus supplement and accompanying prospectus relating to the offering has been filed with the SEC and is available on the SEC's website at Copies of the final prospectus supplement and the accompanying prospectus may also be obtained by contacting TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, NY 10017, by telephone at (833) 297-2926 or by email at or Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at 1-888-603-5847, or by email at barclaysprospectus@ This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About Senseonics Senseonics Holdings, Inc. ("Senseonics") is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM systems Eversense® 365 and Eversense® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone. Forward-Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including without limitation statements regarding, among other things, Senseonics' expectations about the anticipated use of proceeds from the offerings. The words 'expects,' 'potential,' 'may,' 'will,' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including uncertainties relating to the current economic environment, market and other conditions; and other risks and uncertainties that are described in the Risk Factors section of Senseonics' Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 3, 2025, Senseonics' Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 8, 2025, Senseonics' final prospectus supplement for the public offering dated May 15, 2025, filed with the SEC on May 16, 2025, and other filings Senseonics makes with the SEC from time to time. The events and circumstances discussed in such forward-looking statements may not occur, and Senseonics' actual results could differ materially and adversely from those anticipated or implied thereby. Any forward-looking statements contained in this press release speak only as of the date hereof, and Senseonics expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise. INVESTOR CONTACT:Jeremy FefferLifeSci Advisorsinvestors@
Yahoo
16-05-2025
- Business
- Yahoo
Senseonics Announces Pricing of $50 Million Public Offering of Common Stock and Concurrent Private Placement
GERMANTOWN, Md., May 15, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced the pricing of an underwritten public offering of 100,000,000 shares of common stock at a price to the public of $0.50 per share of common stock. The gross proceeds to Senseonics from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be $50,000,000. In addition, Senseonics granted the underwriters a 30-day option to purchase up to an additional 15,000,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on May 19, 2025, subject to satisfaction of customary closing conditions. TD Cowen and Barclays are acting as joint book-running managers and RBC Capital Markets and Lake Street are acting as bookrunners for the proposed offering. The proposed offering is being made pursuant to a 'shelf' registration statement on Form S-3, including a base prospectus (File No. 333-273882) that was originally filed with the Securities and Exchange Commission (the 'SEC') on August 10, 2023 and became effective on September 12, 2023. A preliminary prospectus supplement and accompanying prospectus relating to the proposed offering were filed with the SEC and are available on the SEC's website at A final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available for free on the SEC's website located at Copies of the final prospectus supplement and accompanying prospectus may be obtained, when available, by contacting TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, NY 10017, by telephone at (833) 297-2926 or by email at or Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at 1-888-603-5847, or by email at barclaysprospectus@ Pursuant to the terms of a Securities Purchase Agreement with Abbott Laboratories ('Abbott') dated May 15, 2025, Abbott will purchase shares of Senseonics' common stock in a separate private placement at $0.50 per share ('Concurrent Private Placement') representing 4.99% of Senseonics' outstanding common stock post-offering. The Concurrent Private Placement is expected to close on May 21, 2025, subject to the closing of the public offering and other customary closing conditions. Senseonics intends to use the net proceeds from the public offering and the Concurrent Private Placement to fund the ongoing launch of Eversense 365 and continued development of pipeline products, as well as for working capital and general corporate purposes. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. About Senseonics Senseonics Holdings, Inc. ("Senseonics") is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM systems Eversense® 365 and Eversense® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including without limitation statements regarding, among other things, Senseonics' expectations about the closing date of the offering and the anticipated use of proceeds from the offering and the Concurrent Private Placement. The words 'expects,' 'potential,' 'may,' 'will,' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including risks relating to Senseonics' inability, or the inability of underwriters, to satisfy the conditions to closing for the offering; failure to satisfy the closing conditions of the Concurrent Private Placement; uncertainties relating to the current economic environment, market and other conditions; and other risks and uncertainties that are described in the Risk Factors section of Senseonics' Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 3, 2025, Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 8, 2025, and other filings Senseonics makes with the SEC from time to time. The events and circumstances discussed in such forward-looking statements may not occur, and Senseonics' actual results could differ materially and adversely from those anticipated or implied thereby. Any forward-looking statements contained in this press release speak only as of the date hereof, and Senseonics expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise. INVESTOR CONTACT:Jeremy FefferLifeSci Advisorsinvestors@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
29-04-2025
- Business
- Yahoo
Sequel Med Tech and Senseonics Integrate Technologies to Create First Automated Insulin Delivery (AID) System with One-Year Continuous Glucose Monitor (CGM)
twiist™ expands compatibility offerings to become the first AID system compatible with Senseonics Eversense® 365 one-year CGM system twiist with Eversense 365 launch expected in Q3 MANCHESTER, N.H. and GERMANTOWN, Md., April 29, 2025 (GLOBE NEWSWIRE) -- Sequel Med Tech, LLC, a company developing state-of-the-art insulin delivery technologies, and Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable CGM systems for people with diabetes, today announced their commercial development agreement to integrate Sequel's twiist Automated Insulin Delivery (AID) System powered by Tidepool with Senseonics' Eversense 365 CGM. Through this collaboration, the twiist™ Automated Insulin Delivery (AID) System will become the first AID system compatible with the Senseonics Eversense 365, the world's first and only one-year CGM system, offering people with type 1 diabetes a new level of flexibility and personalization in their diabetes management. The agreement between Sequel and Senseonics will provide individuals with type 1 diabetes the option of a one-year CGM system that integrates with the twiist AID System. The integrated system aims to enhance diabetes management by offering people with diabetes more tools to manage care, which may lead to improved glucose control, increased convenience, and provide greater flexibility. 'Sequel is committed to investing in innovations that empower people with diabetes with options in how they manage their diabetes,' said Sequel CEO and Co-Founder Alan Lotvin, M.D. 'By partnering with Senseonics, a company pioneering long-duration CGM, we aim to deliver the flexibility people want to personalize their diabetes management on their terms.' 'This collaboration with Sequel marks a significant step forward in transforming diabetes care,' said Tim Goodnow, PhD, President and CEO of Senseonics. 'People with diabetes who choose the convenience and ease of our one-year CGM sensor have been waiting for a compatible AID system to enhance their diabetes management. The synergy of Eversense and twiist will provide people with diabetes our most recent innovations in advanced pump, algorithm, and sensor technologies to simplify diabetes management, providing users with an AID solution that unlocks the full experience of our year-long CGM technology.' Sequel remains committed to advancing diabetes technology and expanding partnerships to give people with diabetes more choice and flexibility in how they manage their diabetes. People living with type 1 diabetes who choose to use twiist will have the flexibility to select from two compatible CGM partners, the Senseonics Eversense 365 and Abbott's FreeStyle Libre 3 Plus sensor, to best suit their individual needs for managing diabetes. In September 2024, Eversense 365 received FDA clearance as an integrated continuous glucose monitoring (iCGM) system for people with diabetes, paving the way for its use within an automated insulin delivery (AID) system. United by a shared commitment to simplifying diabetes management and improving quality of life, Senseonics and Sequel have begun work to integrate Senseonics' newest generation one-year sensor, Eversense 365, with twiist, Sequel's state-of-the-art AID system. This expanded CGM compatibility between Eversense and twiist will mark a significant advancement—offering greater personalization, more choice, and the potential for improved outcomes for people living with diabetes. The integration is expected to be available in the third quarter of this year. About twiist The twiist AID System is the first insulin delivery system that directly measures the volume of insulin delivered with every micro-dose. Cleared for people ages six and up with type 1 diabetes, the twiist AID System offers the capability and flexibility to address each person's individual dosing needs. The twiist Loop algorithm, based on the diabetes community-driven Tidepool Loop, allows the system to automatically adjust basal insulin delivery based on real-time sensor readings and predicted glucose levels. For more information about twiist, set to be commercially available in Q2 2025, please visit About Sequel Med Tech Headquartered in Manchester, N.H., Sequel Med Tech, LLC is developing the next generation of transformative drug-delivery advancements. Sequel's approach is to look at disease management holistically to advance systems that make living with disease simpler and easier for all. Its FDA-cleared innovation, the twiist® Automated Insulin Delivery (AID) system, integrates novel technologies to reimagine insulin delivery and sets a new standard for drug delivery. Co-founded by visionary Dean Kamen, serial entrepreneur Pablo Legorreta, seasoned medical device executive Bill Doyle and healthcare visionary Alan Lotvin, MD. Sequel is bringing the latest developments in science and technology to help drive more accessible drug delivery. For more information, visit and About Eversense Eversense 365 is developed by Senseonics and brought to patients by Ascensia Diabetes Care, a subsidiary of PHC Holdings Corporation (TSE: 6523). As the only implantable CGM available, it offers patients a truly differentiated CGM experience, providing One Year of exceptionally accurate monitoring with minimal interruptions. It benefits endocrinologists and care teams by offering their patients confidence in decision-making, long-term peace of mind and enhanced quality of life with just one CGM. The unique approach also allows people to overcome common frustrations and interruptions experienced with traditional, short-term CGMs, so that patients can focus on managing their diabetes and not their CGM. The Eversense® Continuous Glucose Monitoring (CGM) Systems are indicated for continually measuring glucose levels for up to 365 days for Eversense® 365 and 180 days for Eversense® E3 in persons with diabetes age 18 and older. The systems are indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time per week after day 13 for Eversense® 365 and one time per day after day 21 for Eversense® E3, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense CGM Systems are prescription devices; patients should talk to their health care provider to learn more. For important safety information, see A media kit for Eversense 365, including images, logos and further information, can be accessed at About Senseonics Senseonics Holdings, Inc. ("Senseonics") is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM system Eversense® 365 includes a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone. Forward Looking Statements Any statements in this press release about the expectations regarding potential impact on people with diabetes' and providers' experience, benefits and outcomes, statements regarding the results, success and timeline for completion of the integration, and other statements containing the words "believe," 'expect,' 'intend,' 'may,' 'projects,' 'will,' 'planned,' and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties inherent in the new product launch and ongoing commercialization of Eversense 365, uncertainties inherent in the coordination with third parties and new partners, uncertainties inherent in the development of new technologies, uncertainties in insurer, regulatory and administrative processes and decisions, uncertainties in prescriber and patient decisions and responses to new technology or initiatives, and such other factors as are set forth in the risk factors detailed in Senseonics' Annual Report on Form 10-K for the year ended December 31, 2023 and subsequent quarterly reports on Form 10-Q filed with the SEC under the heading "Risk Factors." In addition, the forward-looking statements included in this press release represent Senseonics' views as of the date hereof. Senseonics anticipates that subsequent events and developments will cause Senseonics' views to change. However, while Senseonics may elect to update these forward-looking statements at some point in the future, Senseonics specifically disclaims any obligation to do so except as required by law. These forward-looking statements should not be relied upon as representing Senseonics' views as of any date subsequent to the date hereof. Sequel Media ContactGreta GustafsonHighwire Senseonics Investor ContactJeremy FefferLifeSci Advisorsinvestors@ in to access your portfolio
Yahoo
26-02-2025
- Business
- Yahoo
Eversense 365 and SweetSpot Integrate Software to Optimize Diabetes Care
Senseonics and Ascensia integrate software between SweetSpot and Eversense 365, the world's first and only One Year CGM system SweetSpot partners with endocrinology practices to provide virtual CGM monitoring and enhanced patient care GERMANTOWN, Md. and PARSIPPANY, N.J., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE: SENS) and Ascensia Diabetes Care announce the software integration of SweetSpot™ with the Eversense® 365 Continuous Glucose Monitoring (CGM) System in the U.S. This software integration provides endocrinology practices that partner with SweetSpot the ability to continue to improve patient care by seamlessly and regularly reviewing data from patients using Eversense 365, the world's first and only One Year CGM. SweetSpot combines a centralized software platform for managing diabetes device data with wrap-around clinical support services. SweetSpot's virtual team of Certified Diabetes Care and Education Specialists (CDCES) perform monthly CGM data reviews and coordinate with providers and patients on treatment plan assessment and changes. By developing an integration with Eversense 365, SweetSpot can work alongside practices to act on this unique system's CGM data in between patients' scheduled appointments, allowing for more personalized support. These regular data reviews help ensure patients get timely treatment adjustments, keeping them better connected to their diabetes care team year-round with a goal of improving glycemic control. Practices can also unlock new opportunities through SweetSpot's automated capture of reimbursable care events, making partnering with SweetSpot both clinically impactful and operationally efficient. Eversense 365 is developed by Senseonics and brought to patients by Ascensia Diabetes Care, a subsidiary of PHC Holdings Corporation (TSE: 6523). As the only implantable CGM available, it offers patients a truly differentiated CGM experience, providing One Year of exceptionally accurate monitoring with minimal interruptions. It benefits endocrinologists and care teams by offering their patients confidence in decision-making, long-term peace of mind and enhanced quality of life with just one CGM. The unique approach also allows people to overcome common frustrations and interruptions experienced with traditional, short-term CGMs, so that patients can focus on managing their diabetes and not their CGM. Dr Ralph Oiknine, Physician, Co-Founder and Chief Medical Officer of SweetSpot, said: 'SweetSpot removes all the barriers to implementing a strong, virtual CGM monitoring program for endocrinology practices and all providers involved in diabetes care. Our dedicated team is passionate about transforming how diabetes is managed – and making sure that no opportunities are missed to use the rich data from CGMs for improved care. This integration with Eversense reinforces SweetSpot's commitment to seamless diabetes management, driving better patient outcomes and practice growth for our partners by integrating more CGM options, such as the only implantable CGM on the market.' Mukul Jain, Chief Operating Officer of Senseonics, added: 'We are pleased to enable integration with SweetSpot to help healthcare providers using the software platform to optimize care for patients using Eversense 365. Our CGM offers a completely fresh approach to diabetes management by collecting a whole year of glucose data with just one CGM. We continue to focus on bringing Eversense 365 to more people across the country and are excited to see how integrations like this can further enhance our compelling offering for patients and healthcare providers.' Dr. Jacob Vadakekalam of the Diabetes & Glandular Disease (DGD) Clinic in San Antonio, Texas, added: 'As a doctor committed to providing the best care possible, I am pleased about the partnership between SweetSpot and Eversense. This collaboration represents a step forward in healthcare integration, and I believe it will have a positive impact on diabetes management for my patients here at the Diabetes & Glandular Disease Clinic and in turn minimizing future hospitalizations.' Notes for Editors About Eversense The Eversense® Continuous Glucose Monitoring (CGM) Systems are indicated for continually measuring glucose levels for up to 365 days for Eversense® 365 and 180 days for Eversense® E3 in persons with diabetes age 18 and older. The systems are indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time per week after day 13 for Eversense® 365 and one time per day after day 21 for Eversense® E3, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense CGM Systems are prescription devices; patients should talk to their health care provider to learn more. For important safety information, see A media kit for Eversense 365, including images, logos and further information, can be accessed at About SweetSpot SweetSpot partners with endocrinology practices to provide virtual CGM monitoring and enhanced patient care. SweetSpot combines a centralized software platform for managing diabetes device data, such as data from CGMs and insulin pumps, with wrap-around clinical support services. SweetSpot's virtual team of Certified Diabetes Care and Education Specialists (CDCES) perform monthly CGM data reviews and coordinate with providers and patients to facilitate treatment plan changes. By actively managing and remotely reviewing CGM data between patient visits, we ensure patients receive timely treatment adjustments to improve glycemic control and patient outcomes. Additionally, SweetSpot's automated capture of reimbursable care events optimizes CPT code utilization, unlocking new revenue streams for practices and making our partnerships both clinically effective and financially more information, visit About Senseonics Senseonics Holdings, Inc. ("Senseonics") is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM system Eversense® 365 includes a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone. About Ascensia Diabetes Care Ascensia Diabetes Care is a global company focused entirely on helping people with diabetes. Our mission is to empower those living with diabetes through innovative solutions that simplify and improve their lives. We are home to the world-renowned CONTOUR® portfolio of blood glucose monitoring systems and the exclusive global distribution partner for the Eversense® Continuous Glucose Monitoring Systems from Senseonics. These products combine advanced technology with user-friendly functionality to help people with diabetes manage their condition and make a positive difference to their lives. As a trusted partner in the diabetes community, we collaborate closely with healthcare professionals and other partners to ensure our products meet the highest standards of accuracy, precision and reliability, and that we conduct our business compliantly and with integrity. Ascensia is a member of PHC Group and was established in 2016 through the acquisition of Bayer Diabetes Care by PHC Holdings Corporation. Ascensia products are sold in more than 100 countries. Ascensia has around 1,400 employees and operations in 29 countries. For further information, please visit the Ascensia Diabetes Care website at: About PHC Holdings Corporation PHC Holdings Corporation (TSE 6523) is a global healthcare company with a mission of contributing to the health of society through healthcare solutions that have a positive impact and improve the lives of people. Its subsidiaries (referred to collectively as PHC Group) include PHC Corporation, Ascensia Diabetes Care Holdings AG, Epredia Holdings Ltd., LSI Medience Corporation, Mediford Corporation, and Wemex. Together, these companies develop, manufacture, sell and service solutions across diabetes management, healthcare solutions, life sciences and diagnostics. PHC Group's consolidated net sales in FY2023 were JPY 353.9 billion with global distribution of products and services in more than 125 countries. Forward Looking Statements Any statements in this press release about the expectations regarding potential impact on patients' and providers' experience and outcomes, and other statements containing the words "believe," 'expect,' 'intend,' 'may,' 'projects,' 'will,' 'planned,' and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties inherent in the new product launch and ongoing commercialization of Eversense 365, uncertainties inherent in the coordination with third parties and new partners, uncertainties in prescriber and patient decisions and responses to new technology or initiatives, and such other factors as are set forth in the risk factors detailed in Senseonics' Annual Report on Form 10-K for the year ended December 31, 2023 and subsequent quarterly reports on Form 10-Q filed with the SEC under the heading "Risk Factors." In addition, the forward-looking statements included in this press release represent Senseonics' views as of the date hereof. Senseonics anticipates that subsequent events and developments will cause Senseonics' views to change. However, while Senseonics may elect to update these forward-looking statements at some point in the future, Senseonics specifically disclaims any obligation to do so except as required by law. These forward-looking statements should not be relied upon as representing Senseonics' views as of any date subsequent to the date hereof. Ascensia Communications Contact: Tim StamperFTI Senseonics Investor Contact Jeremy FefferLifeSci Advisorsinvestors@ SweetSpot Communications Contact: Joelle FredmanDirector of Marketingjfredman@ in to access your portfolio
